rabbit anti bace1 (Abcam)
Abcam is a verified supplier 
99
Structured Review
Abcam
rabbit anti bace1
Rabbit Anti Bace1, supplied by Abcam, used in various techniques. Bioz Stars score: 99/100, based on 2153 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ab102396/Recombinant+Anti-Transcription+factor+AP-2-alpha+antibody/pmc05895038-539-15-17
Average 99 stars, based on 2153 article reviews
Rabbit Anti Bace1, supplied by Abcam, used in various techniques. Bioz Stars score: 99/100, based on 2153 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ab102396/Recombinant+Anti-Transcription+factor+AP-2-alpha+antibody/pmc05895038-539-15-17
Average 99 stars, based on 2153 article reviews
rabbit anti bace1 - by Bioz Stars,
2026-09
99/100 stars
Images
1) Product Images from "β-Secretase BACE1 Promotes Surface Expression and Function of Kv3.4 at Hippocampal Mossy Fiber Synapses"
Article Title: β-Secretase BACE1 Promotes Surface Expression and Function of Kv3.4 at Hippocampal Mossy Fiber Synapses
Journal: The Journal of Neuroscience
doi: 10.1523/JNEUROSCI.2643-17.2018
Figure Legend Snippet: BACE1 and Kv3.4 colocalize in the MF pathway of the hippocampus. A, Immunofluorescence staining showing prominent Kv3.4 signal in the hilar region and in the MF tract. Staining was performed with the rabbit-anti-Kv3.4 antibody and DAPI in 1-month-old BACE1 WT (left, n = 5) and KO (right, n = 4) mice. Scale bar, 500 μm. B, Double staining for Kv3.4 (left, mouse-anti-Kv3.4 antibody) and BACE1 (middle, rabbit-anti-BACE1 antibody; Abcam) with superposition of images (right) shows a distinct colocalization in the hippocampus of 1-month-old BACE1 WT mice. Scale bar, 500 μm. Higher-magnification images below show the hilar region (right) and the end of the MF tract (left), n = 3. Scale bar, 50 μm. C, Double staining of Kv3.4 and BACE1 with higher-magnification images as described in B for hippocampal slices of age-matched KO mice, n = 3. Scale bars as in B.
Techniques Used: Immunofluorescence, Staining, Double Staining
Figure Legend Snippet: Kv3.4 surface levels are reduced in the hippocampus of BACE1 KO mice. A, Representative Western blot of a hippocampal slice biotinylation for a WT/KO set. B, Total protein levels were densitometrically quantified, normalized to β-actin, and each KO sample was normalized to the corresponding WT that had been set to 1. Red column shows total Kv3.4 protein in KO and results for the positive control CNTN2 are illustrated in the gray column. C, Surface proteins were quantified and normalized to the corresponding levels of pan-cadherin or Na+-K+-ATPase and KO samples were normalized to WT according to B. Results of KO mice reveal a significant decrease in surface level for Kv3.4 (red columns) and a significant increase for CNTN2 (gray columns). WT/KO, n = 4 pairs, *p < 0.05, **p < 0.01, two-tailed one-sample t test.
Techniques Used: Western Blot, Positive Control, Two Tailed Test
Figure Legend Snippet: BACE1 alters Kv3.4 trafficking in cultured hippocampal neurons. A, Left, Immunofluorescence double staining in a hippocampal neuron obtained from WT transfected with Kv3.4-EGFP and BACE1 (left: green, mouse-anti-Kv3.4 antibody; red, rabbit-anti-BACE1 antibody; Abcam; and DAPI). Scale bar, 20 μm. Right, Higher-magnification images of the indicated region along the axon. Scale bar, 10 μm. WT, n = 8 axons; KO, n = 3 axons. Double staining was performed in transfected hippocampal neurons at 6–7 DIV in three independent WT and two KO cultures. B–D, Axonal transport of Kv3.4-EGFP in transfected hippocampal neurons of WT was imaged at 6–8 DIV. Images were sampled every 530 ms for 6 min before and after bleaching the axonal segment. B, This frame of an image series shows an axon (top) and a representative part of the corresponding kymographs before (middle) and after bleaching (lower). C, D, Graphs demonstrating the cumulative probabilities for velocities of Kv3.4-EGFP vesicles moving in anterograde or retrograde direction depending on BACE1 coexpression (anterograde: Kv3.4-EGFP, n = 863, + BACE1, n = 788; bleached: Kv3.4-EGFP, n = 680, + BACE1, n = 565; retrograde: Kv3.4-EGFP, n = 875, + BACE1, n = 810; bleached: n = 378, + BACE1, n = 346). Data were obtained from three independent cultures. ***p < 0.001, two-tailed Mann–Whitney test applied to all unbinned vesicle velocities.
Techniques Used: Cell Culture, Immunofluorescence, Double Staining, Transfection, Two Tailed Test, MANN-WHITNEY
Figure Legend Snippet: BACE1-null mice show reduced Kv3.4 level in hippocampal synapses. A, Representative Western blot of hippocampal fractions showing total, cytosolic, and synaptic fraction of 1-month-old BACE1 WT and KO mice. B, Synaptic level of the indicated proteins was quantified and normalized to corresponding β-actin levels. WT (white columns) was set to 1 for illustration. The red column shows the KO result for Kv3.4, the gray columns for other synaptic K+ channels and synaptic markers. n = 3 for each genotype, *p < 0.05, **p < 0.01, two-tailed two-sample t test.
Techniques Used: Western Blot, Two Tailed Test
Figure Legend Snippet: Mice treated with the BACE inhibitor NB-360 show no significant decrease in Kv3.4 levels at hippocampal synapses. A, Representative Western blot of hippocampal fractions showing cytosolic and synaptic proteins of 2-month-old C57BL/6 mice, which were fed food pellets containing BACE inhibitor NB-360 or control pellets for 4 weeks. B, Synaptic level of the indicated proteins quantified and normalized to the corresponding β-actin levels. Untreated controls (white columns) were set to 1 for illustration. Red column shows Kv3.4 results from treated mice. Gray columns depict results for the BACE1 substrates CNTN2 and APP, synaptic marker proteins synapsin-1 and PSD-95, and for BACE1 protein in NB-360-fed mice. C, Scatter plot demonstrating the synaptic protein level of Kv3.4 for each investigated animal. Bar indicates mean. D, Correlation analysis of BACE1 versus Kv3.4 expression. Pearson's r = 0.79. n = 8 for treatment and control group, **p < 0.01, ***p < 0.001. n.s., Not significant, two-tailed two-sample t test.
Techniques Used: Western Blot, Marker, Expressing, Two Tailed Test
Figure Legend Snippet: Reduced Kv3 current leads to altered synaptic transmission in BACE1 KO. A, MFs from BACE1 KO mice manifested a reduced I/O relationship for MF-fEPSP. Peak amplitudes were plotted as a function of stimulus intensity. Corresponding fiber volley amplitudes are depicted in the inset. WT, n = 16 slices; KO, n = 18 slices. B, C, I/O curves determined after 2 min (control) and 30 min with 100 μm 4-AP (B) or 30 μm BDS-I (C) in the recording pipette and plotted as described above. The inserts in B depict MF-fEPSP traces from BACE1 WT and KO mice showing responses at 150 μA, 2 min after pipette insertion (black), and after 30 min (blue). WT, n = 7 slices; KO, n = 5 slices (B); WT, n = 5 slices; KO, n = 7 slices (C) D, Histograms summarizing the magnitude of drug effect on MF-fEPSP and MF-fiber volley at a stimulating intensity of 150 μA for WT and KO. E, Insert, Typical MF-fEPSP in response to 5 stimuli at 20 Hz (50 ms interspike interval) recorded from WT. The diagram shows the normalized MF-fEPSP amplitude relative to that of the first MF-fEPSP. WT, n = 15 slices; KO, n = 18 slices. F, Train stimuli determined after 5 min (control) and 35 min with 30 μm BDS-I in the recording pipette and plotted as in E. WT, n = 5 slices; KO, n = 7 slices. *p < 0.05, **p < 0.01, ***p < 0.001, two-tailed two-sample t test (A, D, E), two-tailed paired-sample t test (B, C, F).
Techniques Used: Transmission Assay, Transferring, Two Tailed Test
![BACE1 amplifies Kv3.4 current and alters channel kinetics in a heterologous expression system. A1 and A2 show representative currents of a cell expressing Kv3.4 (A1) or Kv3.4 with BACE1 (A2) recorded with the activation protocol shown in the inset. B1 and B2 display representative currents of a Kv3.4-expressing (B1) or Kv3.4 + BACE1-expressing (B2) cell recorded with the inactivation protocol shown in the inset. C, The I–V relationship was generated from Kv3.4 peak currents plotted as function of test potentials from −50 mV to +30 mV, Kv3.4, n = 60; + BACE1, n = 44. D, Relative noninactivating current was calculated as steady-state current divided by peak current. Peak current was determined from the test pulse at +30 mV after a prepulse at −120 mV (B1, B2, prepulse duration 500 ms). Steady-state current was obtained from recordings with a prepulse at +20 mV that activated and inactivated approximately all channels, resulting in no peak and only noninactivating steady-state current at +30 mV. This steady-state current was averaged over the last 28 ms of the test pulse (see arrow in B1 and B2). Kv3.4, n = 49; + BACE1, n = 36. E, Voltage-dependent activation (squares) and inactivation (triangles) curves. Activation: conductance was generated from mean peak current (C). The graphs present the mean conductance fitted with a Boltzmann equation and normalized to the upper asymptote. Kv3.4, n = 60; + BACE1, n = 44. Inactivation: current amplitudes of individual recordings from test pulses after prepulses of −60 mV to +20 mV recorded with the inactivation protocol (B1) were fitted with a Boltzmann equation. Peak current values were normalized to the upper asymptote. Kv3.4, n = 49; + BACE1, n = 36. F, Activation and inactivation time constants were estimated from recordings with the activation protocol (A1). Rise and decay at 0 mV and +10 mV were fitted using a biexponential function to determine activation and inactivation kinetics, respectively. 0 mV: Kv3.4, n = 50; + BACE1, n = 38; +10 mV: Kv3.4, n = 50; + BACE1, n = 39. Statistical significance of time constants was tested on logarithmically transformed data. For illustration, time constant means ± SEM were back-transformed to a linear scale. G, Time-dependent recovery from channel inactivation recorded with the protocol shown in the inset with varying interpulse intervals Δt = 2i [ms], i = 1–12. Graph shows time-dependent recovery of peak current after inactivation (IΔt) normalized to the peak before channel inactivation (I). Kv3.4, n = 44; + BACE1, n = 23. H, Representative currents of a cell expressing Kv3.4 or Kv3.4 + BACE1 in response to 10 command protocols of the AP waveform with 1 Hz. I, Graphs generated from Kv3.4 peak currents recorded with the command protocol shown in H. Kv3.4, n = 50; + BACE1, n = 42. D, E Inactivation, F, G, I, Cells with peak currents <2 nA at +80 mV in the activation protocol (A1) were excluded from analysis. Statistics: **p < 0.01, ***p < 0.001, normally distributed data were tested using a two-tailed two-sample t test (F); datasets showing no normal distribution were tested using a two-tailed Mann–Whitney test (C, D, G, I).](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_5038/pmc05895038/pmc05895038__zns9991806770007.jpg "BACE1 amplifies Kv3.4 current and alters channel kinetics in ...")
Figure Legend Snippet: BACE1 amplifies Kv3.4 current and alters channel kinetics in a heterologous expression system. A1 and A2 show representative currents of a cell expressing Kv3.4 (A1) or Kv3.4 with BACE1 (A2) recorded with the activation protocol shown in the inset. B1 and B2 display representative currents of a Kv3.4-expressing (B1) or Kv3.4 + BACE1-expressing (B2) cell recorded with the inactivation protocol shown in the inset. C, The I–V relationship was generated from Kv3.4 peak currents plotted as function of test potentials from −50 mV to +30 mV, Kv3.4, n = 60; + BACE1, n = 44. D, Relative noninactivating current was calculated as steady-state current divided by peak current. Peak current was determined from the test pulse at +30 mV after a prepulse at −120 mV (B1, B2, prepulse duration 500 ms). Steady-state current was obtained from recordings with a prepulse at +20 mV that activated and inactivated approximately all channels, resulting in no peak and only noninactivating steady-state current at +30 mV. This steady-state current was averaged over the last 28 ms of the test pulse (see arrow in B1 and B2). Kv3.4, n = 49; + BACE1, n = 36. E, Voltage-dependent activation (squares) and inactivation (triangles) curves. Activation: conductance was generated from mean peak current (C). The graphs present the mean conductance fitted with a Boltzmann equation and normalized to the upper asymptote. Kv3.4, n = 60; + BACE1, n = 44. Inactivation: current amplitudes of individual recordings from test pulses after prepulses of −60 mV to +20 mV recorded with the inactivation protocol (B1) were fitted with a Boltzmann equation. Peak current values were normalized to the upper asymptote. Kv3.4, n = 49; + BACE1, n = 36. F, Activation and inactivation time constants were estimated from recordings with the activation protocol (A1). Rise and decay at 0 mV and +10 mV were fitted using a biexponential function to determine activation and inactivation kinetics, respectively. 0 mV: Kv3.4, n = 50; + BACE1, n = 38; +10 mV: Kv3.4, n = 50; + BACE1, n = 39. Statistical significance of time constants was tested on logarithmically transformed data. For illustration, time constant means ± SEM were back-transformed to a linear scale. G, Time-dependent recovery from channel inactivation recorded with the protocol shown in the inset with varying interpulse intervals Δt = 2i [ms], i = 1–12. Graph shows time-dependent recovery of peak current after inactivation (IΔt) normalized to the peak before channel inactivation (I). Kv3.4, n = 44; + BACE1, n = 23. H, Representative currents of a cell expressing Kv3.4 or Kv3.4 + BACE1 in response to 10 command protocols of the AP waveform with 1 Hz. I, Graphs generated from Kv3.4 peak currents recorded with the command protocol shown in H. Kv3.4, n = 50; + BACE1, n = 42. D, E Inactivation, F, G, I, Cells with peak currents <2 nA at +80 mV in the activation protocol (A1) were excluded from analysis. Statistics: **p < 0.01, ***p < 0.001, normally distributed data were tested using a two-tailed two-sample t test (F); datasets showing no normal distribution were tested using a two-tailed Mann–Whitney test (C, D, G, I).
Techniques Used: Expressing, Activation Assay, Generated, Transformation Assay, Two Tailed Test, MANN-WHITNEY
Figure Legend Snippet: BACE1 interacts directly with Kv3.4. A, B, Representative Western blot of a Kv3.4-IP with BACE1 co-IP (A, n = 3) or BACE1-IP with Kv3.4 co-IP (B, n = 2) and the corresponding isotype controls in transfected HEK293T cells. EGFP served as transfection marker. C, FRAP experiments. Example traces of BACE1-EGFP fluorescence upon coexpression of mCherry (black) or Kv3.4 (red) with corresponding fit curves using the equation I(t)= A * e−t/τ + I0 are shown. D, Recovery time constants of BACE1-EGFP coexpressed with the constructs as indicated below the graph. Statistical significance of time constants was tested on logarithmically transformed data. *p < 0.05, **p < 0.01, one-way ANOVA with post hoc Tukey test. For illustration, time constant means ± SEM were back-transformed to a linear scale. + mCherry, n = 46; + Kv3.4, n = 29; + ENaC-mCherry, n = 31.
Techniques Used: Western Blot, Co-Immunoprecipitation Assay, Transfection, Marker, Fluorescence, Construct, Transformation Assay
Figure Legend Snippet: BACE1 increases Kv3.4 surface level independent of its proteolytic activity in HEK293T cells. A, Representative Western blot of a surface biotinylation experiment of HEK293T cells. Transfected constructs and treatment with 5 μm BACE1 inhibitor IV are depicted above the blot. EGFP served as transfection marker. B, Total levels of Kv3.4 normalized to the corresponding total levels of β-actin, with the normalized levels determined in the absence of BACE1 set to 1. C, Surface levels of Kv3.4 normalized to the corresponding surface levels of pan-cadherin, with the normalized levels determined in the absence of BACE1 set to 1. n = 5, *p < 0.05, two-tailed one-sample t test with Bonferroni correction.
Techniques Used: Activity Assay, Western Blot, Transfection, Construct, Marker, Two Tailed Test
Related Articles
Staining:Article Title: Tau protein modulates an epigenetic mechanism of cellular senescence in human SH-SY5Y neuroblastoma cells Article Snippet: .. Cells were fixed in 4% paraformaldehyde and stained ( ) with primary antibodies: 0.168 μg/mL SUZ12, 0.842 μg/mL EZH2, 1.6 μg/mL H3K27me3 or 1.5 μg/mL Membrane:Article Title: AS-IV enhances the antitumor effects of propofol in NSCLC cells by inhibiting autophagy Article Snippet: Next proteins (20 μg/lane) were dissolved by 10% SDS-PAGE and then electrotransferred onto a PVDF membrane (Millipore). .. After that, the membrane was incubated with specific primary antibodies, including anti-Beclin 1 (ab207612, 1:2,000, Abcam), Incubation:Article Title: AS-IV enhances the antitumor effects of propofol in NSCLC cells by inhibiting autophagy Article Snippet: Next proteins (20 μg/lane) were dissolved by 10% SDS-PAGE and then electrotransferred onto a PVDF membrane (Millipore). .. After that, the membrane was incubated with specific primary antibodies, including anti-Beclin 1 (ab207612, 1:2,000, Abcam), Article Title: Chemoresistant fibroblasts dictate neoadjuvant chemotherapeutic response of head and neck cancer via TGFα-EGFR paracrine signaling Article Snippet: .. The permeabilization and blocking steps were performed by incubating the slides in blocking solution containing PBS (pH 7.4, 25 °C)/0.1% triton-X-100/3% BSA for 30 min, which were then incubated with mouse mAb against human/mouse α-smooth muscle actin (α-SMA)-Cy3TM antibody (Cat no.#C6198-2ML, Sigma Aldrich (1 in 500 dilution)), rabbit mAb against human PDGFRα (Cat no.#3174, Cell Signaling Technology (1 in 1000 dilution)), other:Article Title: Subventricular zone cytogenesis provides trophic support for neural repair in a mouse model of stroke Article Snippet: Primary antibodies and dilutions were as follows: Rabbit polyclonal anti-ASCL1 (1:1000) Abcam ab74065, Rabbit polyclonal anti-ASCL1 (1:500) Cosmo Bio CAC-SK-T01-003, Rabbit polyclonal anti-CD133 (1:1000) Abcam ab19898, Rabbit monoclonal anti-BDNF (clone EPR1292) (1:1000) Abcam ab108319, Rabbit polyclonal anti-BrdU (1:500) Abcam ab152095, Rat monoclonal anti-BrdU [clone BU1/75 (ICR1)] (1:500) Abcam ab6326, Rabbit polyclonal anti-cleaved caspase 3 (1:500) Cell Signaling #9661, Mouse monoclonal anti-CXCL12 (Clone 79018) (1:200) R&D Systems MAB350, Rabbit monoclonal anti-CXCR4 (clone UMB2) (1:250) Abcam Ab124824, Goat polyclonal anti-DCX (1:500) Santa Cruz Biotech. Blocking Assay:Article Title: Chemoresistant fibroblasts dictate neoadjuvant chemotherapeutic response of head and neck cancer via TGFα-EGFR paracrine signaling Article Snippet: .. The permeabilization and blocking steps were performed by incubating the slides in blocking solution containing PBS (pH 7.4, 25 °C)/0.1% triton-X-100/3% BSA for 30 min, which were then incubated with mouse mAb against human/mouse α-smooth muscle actin (α-SMA)-Cy3TM antibody (Cat no.#C6198-2ML, Sigma Aldrich (1 in 500 dilution)), rabbit mAb against human PDGFRα (Cat no.#3174, Cell Signaling Technology (1 in 1000 dilution)), |
